Intra-and inter-tumor braf heterogeneity in acral melanoma: An immunohistochemical analysis

Takamichi Ito, Yumiko Kaku-Ito, Maho Murata, Toshio Ichiki, Yuki Kuma, Yuka Tanaka, Taketoshi Ide, Fumitaka Ohno, Maiko Wada-Ohno, Yuichi Yamada, Yoshinao Oda, Masutaka Furue

Research output: Contribution to journalArticle

Abstract

The current development of BRAF inhibitors has revolutionized the treatment of unresectable melanoma. As the potential heterogeneity of BRAF mutations in melanoma has been reported, accurate detection of BRAF mutations are important. However, the genetic heterogeneity of acral melanoma—a distinct type of melanoma with a unique genetic background—has not fully been investigated. We conducted a retrospective review of our acral melanoma patients. Of the 196 patients with acral melanoma, we retrieved 31 pairs of primary and matched metastatic melanomas. We immunostained the 31 pairs with VE1, a BRAFV600E-mutation-specific monoclonal antibody. Immunohistochemistry with VE1 showed a high degree of sensitivity and specificity for detecting BRAFV600E mutations compared with the real-time polymerase chain reaction method. A total of nine primary (29.0%) and eight metastatic (25.8%) acral melanomas were positive for VE1. In three patients (9.7%), we observed a discordance of VE1 staining between the primary and metastatic lesions. Of note, VE1 immunohistochemical staining revealed a remarkable degree of intra-tumor genetic heterogeneity in acral melanoma. Our study reveals that VE1 immunostaining is a useful ancillary method for detecting BRAFV600E mutations in acral melanoma and allows for a clear visualization of intra-and inter-tumor BRAF heterogeneity.

Original languageEnglish
Article number6191
JournalInternational journal of molecular sciences
Volume20
Issue number24
DOIs
Publication statusPublished - Dec 2 2019

Fingerprint

mutations
Tumors
Melanoma
tumors
Extremities
Monoclonal antibodies
Polymerase chain reaction
staining
Neoplasms
Visualization
Monoclonal Antibodies
Mutation
Genetic Heterogeneity
polymerase chain reaction
antibodies
lesions
inhibitors
Staining and Labeling
sensitivity
Real-Time Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Intra-and inter-tumor braf heterogeneity in acral melanoma : An immunohistochemical analysis. / Ito, Takamichi; Kaku-Ito, Yumiko; Murata, Maho; Ichiki, Toshio; Kuma, Yuki; Tanaka, Yuka; Ide, Taketoshi; Ohno, Fumitaka; Wada-Ohno, Maiko; Yamada, Yuichi; Oda, Yoshinao; Furue, Masutaka.

In: International journal of molecular sciences, Vol. 20, No. 24, 6191, 02.12.2019.

Research output: Contribution to journalArticle

Ito, Takamichi ; Kaku-Ito, Yumiko ; Murata, Maho ; Ichiki, Toshio ; Kuma, Yuki ; Tanaka, Yuka ; Ide, Taketoshi ; Ohno, Fumitaka ; Wada-Ohno, Maiko ; Yamada, Yuichi ; Oda, Yoshinao ; Furue, Masutaka. / Intra-and inter-tumor braf heterogeneity in acral melanoma : An immunohistochemical analysis. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 24.
@article{e0ec17524eb6448bad763383c7d1bbae,
title = "Intra-and inter-tumor braf heterogeneity in acral melanoma: An immunohistochemical analysis",
abstract = "The current development of BRAF inhibitors has revolutionized the treatment of unresectable melanoma. As the potential heterogeneity of BRAF mutations in melanoma has been reported, accurate detection of BRAF mutations are important. However, the genetic heterogeneity of acral melanoma—a distinct type of melanoma with a unique genetic background—has not fully been investigated. We conducted a retrospective review of our acral melanoma patients. Of the 196 patients with acral melanoma, we retrieved 31 pairs of primary and matched metastatic melanomas. We immunostained the 31 pairs with VE1, a BRAFV600E-mutation-specific monoclonal antibody. Immunohistochemistry with VE1 showed a high degree of sensitivity and specificity for detecting BRAFV600E mutations compared with the real-time polymerase chain reaction method. A total of nine primary (29.0{\%}) and eight metastatic (25.8{\%}) acral melanomas were positive for VE1. In three patients (9.7{\%}), we observed a discordance of VE1 staining between the primary and metastatic lesions. Of note, VE1 immunohistochemical staining revealed a remarkable degree of intra-tumor genetic heterogeneity in acral melanoma. Our study reveals that VE1 immunostaining is a useful ancillary method for detecting BRAFV600E mutations in acral melanoma and allows for a clear visualization of intra-and inter-tumor BRAF heterogeneity.",
author = "Takamichi Ito and Yumiko Kaku-Ito and Maho Murata and Toshio Ichiki and Yuki Kuma and Yuka Tanaka and Taketoshi Ide and Fumitaka Ohno and Maiko Wada-Ohno and Yuichi Yamada and Yoshinao Oda and Masutaka Furue",
year = "2019",
month = "12",
day = "2",
doi = "10.3390/ijms20246191",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "24",

}

TY - JOUR

T1 - Intra-and inter-tumor braf heterogeneity in acral melanoma

T2 - An immunohistochemical analysis

AU - Ito, Takamichi

AU - Kaku-Ito, Yumiko

AU - Murata, Maho

AU - Ichiki, Toshio

AU - Kuma, Yuki

AU - Tanaka, Yuka

AU - Ide, Taketoshi

AU - Ohno, Fumitaka

AU - Wada-Ohno, Maiko

AU - Yamada, Yuichi

AU - Oda, Yoshinao

AU - Furue, Masutaka

PY - 2019/12/2

Y1 - 2019/12/2

N2 - The current development of BRAF inhibitors has revolutionized the treatment of unresectable melanoma. As the potential heterogeneity of BRAF mutations in melanoma has been reported, accurate detection of BRAF mutations are important. However, the genetic heterogeneity of acral melanoma—a distinct type of melanoma with a unique genetic background—has not fully been investigated. We conducted a retrospective review of our acral melanoma patients. Of the 196 patients with acral melanoma, we retrieved 31 pairs of primary and matched metastatic melanomas. We immunostained the 31 pairs with VE1, a BRAFV600E-mutation-specific monoclonal antibody. Immunohistochemistry with VE1 showed a high degree of sensitivity and specificity for detecting BRAFV600E mutations compared with the real-time polymerase chain reaction method. A total of nine primary (29.0%) and eight metastatic (25.8%) acral melanomas were positive for VE1. In three patients (9.7%), we observed a discordance of VE1 staining between the primary and metastatic lesions. Of note, VE1 immunohistochemical staining revealed a remarkable degree of intra-tumor genetic heterogeneity in acral melanoma. Our study reveals that VE1 immunostaining is a useful ancillary method for detecting BRAFV600E mutations in acral melanoma and allows for a clear visualization of intra-and inter-tumor BRAF heterogeneity.

AB - The current development of BRAF inhibitors has revolutionized the treatment of unresectable melanoma. As the potential heterogeneity of BRAF mutations in melanoma has been reported, accurate detection of BRAF mutations are important. However, the genetic heterogeneity of acral melanoma—a distinct type of melanoma with a unique genetic background—has not fully been investigated. We conducted a retrospective review of our acral melanoma patients. Of the 196 patients with acral melanoma, we retrieved 31 pairs of primary and matched metastatic melanomas. We immunostained the 31 pairs with VE1, a BRAFV600E-mutation-specific monoclonal antibody. Immunohistochemistry with VE1 showed a high degree of sensitivity and specificity for detecting BRAFV600E mutations compared with the real-time polymerase chain reaction method. A total of nine primary (29.0%) and eight metastatic (25.8%) acral melanomas were positive for VE1. In three patients (9.7%), we observed a discordance of VE1 staining between the primary and metastatic lesions. Of note, VE1 immunohistochemical staining revealed a remarkable degree of intra-tumor genetic heterogeneity in acral melanoma. Our study reveals that VE1 immunostaining is a useful ancillary method for detecting BRAFV600E mutations in acral melanoma and allows for a clear visualization of intra-and inter-tumor BRAF heterogeneity.

UR - http://www.scopus.com/inward/record.url?scp=85076284825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076284825&partnerID=8YFLogxK

U2 - 10.3390/ijms20246191

DO - 10.3390/ijms20246191

M3 - Article

C2 - 31817947

AN - SCOPUS:85076284825

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 24

M1 - 6191

ER -